Project Grant R01HL175803
Award Date
6/1/25
Completion Date
3/31/29
Dollars Obligated
$731K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44106, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $692,971 to Case Western Reserve University to conduct a collaborative research project aimed at advancing the understanding of genetic mutations in cardiac myosin binding protein C (cMyBP-C) that can lead to hypertrophic cardiomyopathy. The project integrates molecular biology, biophysics,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $126,306 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Washington. The grant, awarded on December 20, 2024, will fund research to establish a new high-throughput system for reclassifying genetic variants associated with hypertrophic cardiomyopathy (HCM) and to determine the role of potential genetic modifiers that influence the severity of HCM caused by pathogenic MYH7 gene...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), has awarded a $767,579 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Vanderbilt University Medical Center to conduct research aimed at discovering and defining the effects of rare genetic variants on hypertrophic cardiomyopathy (HCM). The project will leverage data from large biobanks comprising over 1.5 million participants and 5,000 HCM cases to address critical knowledge...
This $777,258 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to improve the understanding of heart failure in patients with hypertrophic cardiomyopathy (HCM) through novel cardiac MRI imaging techniques. The principal investigator at the Beth Israel Deaconess Medical Center, Inc. (Bidmc) will leverage advanced cardiac MRI technologies, including diffusion tensor imaging, spectroscopy, and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), will support research to study the impact of cis-regulatory variants on the severity of haploinsufficiency-associated cardiomyopathies. The 5-year, $756,039 award to the Regents of the University of Michigan will enable the researchers to quantify gene expression effects of single nucleotide variants in the cis-regulatory elements of...
This federal Project Grant award of $167,400 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to elucidate the mechanical and metabolic pathways underlying hypertrophic cardiomyopathy caused by MYBPC3 gene mutations. The principal investigator, Dr. Joshua Meisner, will develop novel mouse and induced pluripotent stem cell models to study the progression of this severe, pediatric-onset form of...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $618,045 to the University of Arizona to conduct research focused on improving understanding and treatment of diastolic dysfunction in hypertrophic cardiomyopathy (HCM). The research aims to: 1) fully characterize three key functional domains of the cardiac thin filament related to regulation of relaxation, and determine the effects of...
This $174,050 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research on the molecular basis of contractile dysfunction in human dilated cardiomyopathy. The project aims to investigate the role of the myosin super-relaxed state, a key regulator of cardiac muscle contractility, in depressed cardiac function in dilated cardiomyopathy. Specifically, the research will quantify the proportion...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), will support a $135,840 multiscale computational and experimental investigation of cardiac contractile dysfunction mechanisms in familial cardiomyopathies. The two-year project, starting on September 1, 2024, will focus on understanding how structural perturbations to the myosin motor protein impact its interaction with actin and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $735,085 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Case Western Reserve University (CWRU) to leverage the heat shock transcription factor 1 (HSF1) to transform detrimental age-related clonal hematopoiesis (CH) into a state favoring normal blood cell production. The research aims to understand how deleting HSF1 along with other CH-associated mutations (DNMT3A or TET2) can sustain or enhance...